WO2007138225A1

WO2007138225A1 - Composition for controlling snoring, in the form of a nasal spray

Info

Publication number: WO2007138225A1
Application number: PCT/FR2007/051342
Authority: WO
Inventors: Jean-Christophe Anton
Original assignee: Omega Pharma Capital Nv
Priority date: 2006-06-01
Filing date: 2007-05-29
Publication date: 2007-12-06
Also published as: JP2009538889A; FR2901705A1; AU2007266903A1; MA30488B1; RU2008146887A; EA200802263A1; TNSN08493A1; NO20085138L; BRPI0711231A2; EP2029162A1; CA2653920A1

Abstract

The invention relates to a composition for controlling snoring, characterised in that it comprises: a first substance or combination of substances ensuring a decongestant action in order to increase the nasal light by means of a gentle action on the non-striated muscles, a vasoconstrictive action on the blood vessels, and a local anti-inflammatory action in order to reduce the excessive secretion of mucus and vasodilatory substances; a second substance or combination of substances ensuring the reduction of the air resistance in the nasal valve and around the inferior turbinate bone and the middle turbinate bone by the formation of a 'sliding film ' and the lubrication of the tissues of the nasal passages; and a third substance or combination of substances exhibiting bioadhesive properties and enabling the first and second substance(s) to remain at the site of action thereof.

Description

COMPOSITION FOR FIGHT AGAINST SNORING IN THE FORM OF A NASAL SPRAY

The present invention relates to the field of treatment and prevention of snoring and more particularly snoring in some big snorers.

In the big snorers, a set of complex phenomena is brought into play that produces a characteristic snoring.

In these people, the origin of snoring is frequently pharyngeal and also nasal.

However, the targeted action of certain products on the pharynx and the uvula can not completely solve the problem of some big snorers. It is indeed about intervening on phenomena which imply at the same time the anatomical structures of the nose and the pharynx. Simultaneous action on these two targets can lead to better efficiency.

The general problem of snoring

About 42 to 60% of adults snore occasionally; 20% of men and 10% of women snore in the usual way. Average snoring easily achieves a noise level of 45 dB at 60 dB (the sound of a voice), while a major snoring can exceed 95 dB, which corresponds to the noise of the passage of a truck. In the case of loud snorers, snoring often exceeds 60 dB and can cause serious problems, not only for the snorer himself but also for the people who live alongside him and can not sleep because of the noise. Indeed, among the big snorers and their entourage, the sleep is often disorganized because of the noise and the intensity of the snoring.

The causes of snoring vary from person to person. At the anatomical level, snoring occurs mainly when the airway in the throat (pharynx) narrows after relaxation of the muscles that normally keep the passage open. This narrowing causes turbulent airflow and vibrations at the soft palate and at the base of the tongue, creating the sound of snoring. In the big snorers is superimposed on a snoring whose origin is the pharynx nasal snoring.

The two main causes of nasal snoring are nasal airway obstruction and deformity of the nose. When an obstruction of the nasal passages (congested or blocked nose), the subject requires additional effort to inspire. This action can create a vacuum effect in the throat and a change in the airflow passages in the nasal cavity that cause snoring. In addition, obstruction of the nasal passages requires the subject to breathe through the mouth and is often associated with snoring from the throat. Thus, the onset of snoring in large snorers is due to several factors that interact simultaneously with each other: mainly pharyngeal vibrations and narrowing of the nasal passages.

Snoring at the pharynx

The vibrations in the pharynx are the consequence of a too long veil, a supine sleeping position and a narrowing of the oral cavity.

The existence of a too long veil is the most easily understood factor. This hypertrophy of the veil affects the muscles of the latter relatively especially affects the fatty tissues that surround them, and the mucous membrane. The uvula elongates, the posterior pillars of the tonsils thicken and widen into two half curtains extending the veil downwards. The second factor responsible for the onset of snoring is the supine position (the position on the back of the sleeping body). This position causes the relaxed veil to rest on the posterior wall of the pharynx. In this anatomical position, the passage of the nasal inspiratory air can easily lift it, make it float and vibrate. If the sleeper is lying on his stomach, the veil falls forward, and does not risk touching the posterior or even lateral wall of the pharynx; thus cleared it leaves wide open behind him the air corridor which is posterior to him and the air passes easily. But it is lying on the back that the veil is best applied on the pharynx. This is the usual position of the severe snorer, and it is in this position that the asphyxic risks are greatest.

The narrowing of the oral cavity is the third element responsible for snoring. This narrowing is caused by obesity, nasal obstruction and retrognathism.

In the pharynx, snoring is the vibration of the soft palate and pharyngeal walls under the action of abnormally turbulent airflow. It is related to the anatomical and mechanical features of the pharynx and mucus which constitutes a superficial viscous layer of the pharyngeal tissues. Mucus is a physiological and anatomical element of importance because it constitutes the medium that will interact with the spray (the assets are projected and must act at this level). It is therefore particularly important to know precisely the physical and physiological characteristics of this biological environment.

Between the nasal cavity and the trachea, both rigid and indeformable, the inspiratory air will cross a deformable space, elastic and more or less narrowed. In this narrowing will appear changes of flow and pressure called Venturi phenomena, governed by the Bernouilli theorems, at the origin of the vibration of the walls. Between the nasal fossae and the rigid trachea, the walls of the orohypopharynx are soft, elastic and narrowed. Everything is thus brought together so that Venturi phenomenon occurs several times a second, which accounts for the vibration of the soft palate linked to the clatter of the latter against the walls of the pharynx. However, because of the defense reactions provoked by this inspiratory discomfort, a vicious circle is created with an increase of the inspiratory effort under the effect of this obstruction - destined to fight against the asphyxiation which it entails - but responsible to it is an obstruction that is all the faster and more important that this effort is powerful. This voluntary control being impossible during sleep, a snoring from the moment it settles can only worsen until the awakening or semi-awakening, restoring tone to the muscles of the oropharynx, removes shrinkage and its harmful effects.

For the vibration to occur it is necessary that successively, and about 30 times per minute, the soft veil touches the posterior wall of the pharynx, that it is repelled by a current of air coming from the nose, then that any force bring him back to the palace. In deliberate snoring, this force is the voluntary contraction. In passive nocturnal snoring when lying down, this force is that of gravity, and when it is applied to a long and voluminous veil, this one tends spontaneously to stick on the pharynx.

Snoring at the nasal level

Nasal snoring is the result of narrowing of the nasal passages. The more the tissues relax or the more difficult the passage of air, the greater the risk of snoring. The sound breathing can be caused or accentuated by polyps in the nasal passages (a polyp is an elongated outgrowth that occurs on a mucous membrane); congestion of the nasal passages (colds, allergy, alcohol or tranquillizers absorption) and loosening of the tissues with age.

The nasal cavity is lined with a pseudostratified epithelium that rests on a basement membrane, separating it from the deep submucosal layers. The submucosal layers are composed of mucus, seromucus and serous glands. Local blood flow is distributed to the cells through a network of small arteries, arterioles and arteriovenous anastomoses. Vascular capacitance, formed by veins and cavernous sinusoids, determines the degree of opening of the nasal passages. The contraction or relaxation of this set of vessels is under the influence of the sympathetic system. The cavernous sinusoids are denser than the inferior and middle horns, and are composed of smooth muscle cells controlled by the sympathetic nervous system. A loss of sympathetic tone, or to a lesser degree a cholinergic stimulation causes engorgement of this erectile sinusoidal tissue.

The opening of the nasal passages is controlled mainly by the changes that occur in the capacitance of the vessels. Resistance of the upper nasal passages and indeed responsible for two-thirds of the total air resistance of the airways. The predominant sites of nasal obstruction to the passage of air are the nasal vestibule, nasal valves and nasal turbinates.

There are physiological variations in nasal opening, known as the "nasal cycle". These variations mainly result in changes in the capacitance of the blood vessels in the lower and middle horns. These changes alternate from one nasal cavity to another approximately every two to four hours in 70% of people. The posture is also involved in regulating the degree of vascular congestion. Nasal obstruction increases bilaterally when the subject is in the supine position, and increases unilaterally depending on the lateral position of the subject.

The nasal origin of snoring is an increase in resistance to the passage of air from the upper nasal passages, and more precisely to the level of the nasal valve and the inferior and middle horns. This is the result of a physiopathological mechanism of congestion, resulting in dilation of the blood vessels, increased secretion of mucus, dilation of smooth muscle structures. The resistance to the passage of air increases and modifies the air flows causing soft tissue vibrations of the palate and the uvula.

In the big snorers

It seems that the big snorers physiological changes found in the tracks Nasal and pharyngeal muscles produce characteristic snoring, which is not found in snorers whose snoring origin is either nasal or pharyngeal. The snoring of big snorers is characterized by a particular frequency and intensity.

Snoring at a "standard" buzzer has a frequency between 200 and 2000 Hz, with decibel levels of up to 70 dB. The frequency varies according to the origin of snoring [Perez-Padilla JR, Slawinski E, LM Difrancesco, Feige RR, Remmers JE, Whitelaw WA. Characteristics of the snoring noise in patients with and without occlusive sleep apnea. Am Rev Respir Dis. 1993 Mar; 147 (3): 635-44]. The snoring of big snorers can be quite powerful in intensity. The average of the subjects has a snoring between 40 and 50 dB, with subjects up to 80-90 dB and sometimes even 105 dB. It seems that nasal snoring has a lower intensity than oral snoring. In some big snorers, the intensity of snoring is such that it causes hearing problems in their partners.

The set of changes and physiological disturbances that occur in the big snorers leads to a modification of the air flows at the mouth and nasal levels producing a very large snore, very characteristic both in terms of frequency, intensity and the profile of the recording spectrum.

The big snorers simultaneously present changes in the airflow at the nose as well as vibration of the soft palate. There do not seem to be any changes - anatomical abnormalities typical of big snorers.

In general, large snorers show a strong increase in resistance to the passage of air through the nasal passages, mainly at the level of the nasal valve and the lower and upper horns, which causes a change in the air flow. . This disturbance of the flow results in the production of snoring of nasal origin but also a significant breathing by the mouth generating or reinforcing the vibration of the tissues of the soft palate, in a majority of the cases associated and superimposed to the vibrations of the uvula.

Scientific studies have been conducted to further clarify, in the case of loud snorers, whether there were changes in the pharyngeal cavity, variations in intensity and passage of inspired and exhaled airflows. With these data, the company Persee Médica was able to highlight what was the relationship between the nasal and oral causes of snoring in the big snorers.

LGreen and colleagues show in a study of 18 volunteers, divided into two groups according to whether they were snoring or not, that the volume of the pharyngeal cavity is not different from one group to another [Green DE, Block AJ , Collop NA, Hellard DW. Pharyngeal volume in asymptomatic snorers compared with nonsnoring volunteers. Chest. 1991 Jan; 99 (1): 49-53]. This element is not a discriminating element in big snorers.

The intensity and frequency of snoring are discriminating features, as we saw earlier in the Perez study. Indeed, Snoring of nasal and oral origin have different intensities and different frequencies. In large snorers, the different intensities are superimposed for the same frequency and the intensities are added at different frequencies, which gives this aspect of diffuse noise on the recording spectra.

Stanescu and his team show that the big snorers have problems of limitation of the air inspired and expired [Stanescu D, Kostianev S, Sanna A, Liistro G, Veriter C. Expiratory for limitation during sleep in heavy snorers and obstructive sleep apnoea patients . Eur Respir J. 1996 Oct; 9 (10) .2116-21].

Moreover, the vibration of the soft palate is mainly under the influence of air flows from the nasal passages (often increased following respiratory discomfort). This vibration is itself sustained by a decrease in the tone of the muscles of the pharynx and uvula and produces a local inflammation which in turn increases the atony. A first "vicious circle" is constituted and thus maintains the phenomenon of snoring. Similarly, the vibration of the soft palate causes disturbances of the passage of air during inspiration and expiration and consequently an increase in respiratory effort in the nasal passages. This maintains localized inflammation, congestion and thus enhances the phenomenon. There is thus a second "vicious circle" which reinforces the phenomena causing snoring in the big snorers. This superposition or imbrication of several imbalances produces snoring of very high intensity and characteristic frequency in the big snorers [see figure in appendix]. The prior art

The products marketed against snoring are oil-based preparations for lubricating the mucous membranes of the pharynx or nasal passages. These products are often perceived as inefficient by a large majority of consumers. Indeed, it is often mentioned that these products act quickly but lose their effectiveness in the first hour of sleep, shortly after application.

This finding is explained by the fact that these products do not remain in place at their site of action and are quickly eliminated towards the back throat (oral sprays). Indeed, the velocity of the mucus and the influence of the constant salivary flow cause an elimination of the oily products with as a consequence a weak duration of action.

Some products contain essential oils. The essential oils used in these preparations are, for some of them, not devoid of toxicity. Certain essential oils are indeed subject to restrictions of use and warnings following the demonstration of their toxicity reported by the pharmacovigilance surveys. In addition, the spraying of oily preparations in the pharynx and nasal is associated with the risk of oily pneumonitis, due to the passage of lipid droplets in the lungs. Before the appearance in France of some cases of oily pneumopathies following the administration of anti-inflammatory products containing oils, the French Health Authorities (AFSSAPS) informed the manufacturers of the incriminated products of their concern and asked for additional data on the safety of these products. The risk of passage to the pulmonary level of the oils contained in these preparations represents a certain risk for the safety of the consumer.

Finally, there is no product that allows simultaneous action on the nasal and oral origin of snoring.

Description of the invention

The research work carried out by the Applicant has led to the development of a new strategy for the treatment and prevention of snoring that is particularly adapted to big snorers. Indeed, it is a question of considering that the superposition of a nasal snoring to a snoring whose origin is the pharynx (uvula) and the interactions between these two phenomena result in the production of a sound level of snoring. most important .

In the case of snoring in big snorers, this necessarily implies the establishment of a simultaneous treatment of these two different targets.

This object is achieved according to the invention by virtue of a composition which is preferably in the form of a nasal spray, said composition comprising:

- a first substance or combination of substances providing a decongestant action to increase the nasal light by a sympathetic action on the smooth muscle, a vasoconstrictor action of the blood vessels and a local anti-inflammatory action to reduce excessive secretion mucus and vasodilator substances;

a second substance or combination of substances ensuring the reduction of air resistance at the level of of the nasal valve and the middle and lower horns by the formation of a "sliding mat" and the lubrication of the tissues of the nasal passages;

a third substance or combination of substances having bioadhesive properties and making it possible to maintain at their site of action the first and second substances.

The first substance or combination of substances is selected from the group consisting of: bromelain, Ruscus aculeatus extract and rutin

The second substance or combination of substances is selected from the group consisting of: seawater, glycerin and phosphatidylcholine.

The third substance or combination of substances is selected from the group of carrageenans.

Bromelain enhances the sympathetic action of the smooth muscles of the nasal passages, so as to increase the basal tone, increase the nasal lumen and thus allow better penetration of air into the nasal passages. According to several studies and research, bromelain inhibits the production of prostaglandins responsible for inflammation, and acts on the immune system. Commission E has approved the use of bromelain to treat postoperative and post-traumatic edema, particularly nasal and paranasal sinuses. The anti-inflammatory action of bromelin on the nasal passages has also been confirmed. The results of a clinical trial involving 124 patients hospitalized for bronchitis, pneumonia or other similar lung disorders demonstrated that bromelin resulted in a decrease in mucus viscosity, thereby facilitating its removal from congested airways [Kelly GS. Bromelain: A

Literature Review and Discussion of its Therapeutic Applications. Alt Med Rev 1996; 1 (4): 243-257]. Some authors also suggest bromelain to treat edema and inflammation caused by allergic rhinitis

[Thornhill SM, Kelly AM. Natural treatment of perennial rhinitis allergy. Altern Med Rev. 2000 Oct; 5 (5): 448-54].

The extract of Ruscus aculeatus is intended to cause a vasoconstrictor action of the blood vessels in the form of an adrenergic type action on the smooth muscles of the vessel walls and to increase the nasal lumen and consequently to reduce the resistance to passage of air through the nasal passages. In a 2000 trial involving 148 subjects followed for 12 weeks, an extract of Ruscus aculeatus was more effective than placebo in relieving the symptoms of chronic venous insufficiency by causing vasoconstriction of the walls. veins [Lucker P, Jost V, Wolna P, et al. Efficacy and safety of ruscus extract compared to placebo in patients suffering from chronic venous insufficiency. Phytomedicine. 2000; 7 (suppl. 2): P-155].

Rutin initiates a local anti-inflammatory action to reduce the excessive secretion of mucus and vasodilator substances, so as to reduce edema, vasodilation following inflammation and relaxation of tissue structures of smooth muscle and to allow as a result, an increase in nasal light. Rutin is part of the larger family of bioflavonoids. It is chemically very close to quercetin (another flavonoid), and it has antioxidant, anti-inflammatory, vasoprotective (protection of blood vessels) and anti-thrombotic properties (protection against blood clots). Rutin is present in several medicinal plants, including eucalyptus, hawthorn, ginkgo biloba and St. John's Wort.

Experiments were conducted in animals. They assert that the anti-inflammatory activity of rutin is more pronounced in chronic inflammation than those of other components such as quercetin and hesperidin [Guardia T, Rotelli AE, Juarez AO, Pelzer LE. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rats. Farmaco. 2001 Sep; 56 (9): 683-7].

Glycerine and phosphatidylcholine provide lubrication functions. Seawater provides a sliding mat facilitating the passage of air through the nasal passages by reducing the mechanisms of resistance. Seawater has many therapeutic virtues and mainly locally internal, especially in nasal conditions. Local instillation of saline solution of sea water allows a decrease in inflammation of the nasal mucosa and obtaining a sliding mat. Seawater contains many mineral salts and trace elements that restore the hair functions of the mucosa.

The nasal composition of the invention is remarkable in that it provides lubrication properties of the nasal mucosa and pharynx over a long period thanks to carrageenans, which have bioadhesive properties on the mucous membranes. All of these substances allow the nasal spray to reduce the resistance of the air in the nasal passages. This decrease consequently causes a decrease in the turbulence of the pharyngeal air flows caused by the increase in oral respiration.

In the nasal composition of the invention, and as the first substance or combination of substances:

bromelain, if it is present, represents of the order of 0.01 to 0.05% and preferably of the order of

0.15% by weight of the composition,

the ruscus extract, if it is present, represents of the order of 0.03 to 0.07% and preferably of the order of 0.5% by weight of the composition, rutin, if it is present, represents on the order of 0.01 to 0.05% and preferably of the order of 0.15% by weight of the composition, at least one of the above substances being present in the composition.

In the nasal composition of the invention, and as the second substance or combination of substances:

seawater, if it is present, represents of the order of 0.5 to 5% and preferably of the order of 1% by weight of the composition,

glycerine, if it is present, represents from 1 to 4% and preferably of the order of 2.65% by weight of the composition, phosphatidylcholine, if it is present, represents of the order of 0.5 to 2.5% and preferably of the order of 1.66% by weight of the composition, at least one of the above substances being present in the composition. In particular, the composition comprises a second substance / first substance weight ratio ranging from 20 to 100, especially from 30 to 80, or even from 40 to 70.

In the nasal composition of the invention, and as the third substance or combination of substances, the carrageenans represent of the order of 0.5 to 2% and preferably of the order of 1% of the composition.

The composition may comprise a third substance / first substance weight ratio ranging from 1 to 50, in particular from 2 to 20 or even 5 to 15.

The composition may comprise a second substance / third substance weight ratio ranging from 1 to 50, in particular from 2 to 20 or even 3 to 10.

According to another of its aspects, the subject of the invention is the use of the combination of first, second and third substance as an anti-snoring agent, in particular in large snorers, in a composition, in particular a nasal composition. .

The invention also relates to the combination of the nasal composition above with an oral composition in the form of a mouth spray. Thus, the invention relates to a method for treating or preventing snoring of a subject wherein said subject receives a combination of a nasal composition above with an oral composition in the form of a spray. oral.

Thus, the invention relates to the use of a nasal composition as defined above for the treatment or prevention of snoring in a subject, more particularly in a large snorer, said nasal composition being received by said subject in combination with an oral composition against snoring.

The oral composition comprises at least one lubricating substance and at least one bioadhesive substance capable of adhering said lubricating substance to the mucocilliary cells situated at the level of the pharynx. The bioadhesive substance is selected from the group consisting of: polysaccharides, cellulose derivatives, acrylic derivatives or protein derivatives. Preferably, the bioadhesive substance is a polysaccharide belonging to the carrageenan family.

The oral composition comprises from about 0.5 to about 20% of bioadhesive substance, and in particular carrageenans. This composition contains from 1 to about 5%, and preferably from about 1.5 to 3%, of bioadhesive substance, and in particular of carrageenans. It may also contain about 5 to 20%, and about 10 to 15%, of bioadhesive substance, and in particular of carrageenans.

In the oral composition, the lubricant is a surfactant having a polar portion and a hydrophobic portion. The polar portion of the surfactant is selected from the group consisting of: glucose, sucrose, lactose, glycerol, xylose, peptides, amino acids, nucleotides. The hydrophobic portion is selected from the group consisting of: fatty acids, a fatty alcohol, a fatty amine, esters, glycerides, phospholipids. The hydrophobic part consists of phospholipids, for example phosphatidylcholine.

This oral composition contains approximately 0.5 to 20% of lubricating substance, and in particular of phosphatidylcholine. It may contain preferably from 2 to 10% of lubricating substance, and in particular phosphatidylcholine.

This oral composition further comprises one or more anti-inflammatory agent (s) and / or tonic (s) mucous membranes and pharyngeal tissue. The anti-inflammatory agent is an extract of Filipendula ulmaria, more particularly an extract of flowering heads of Filipendula ulmaria. It contains approximately 0.5 to 5% of anti-inflammatory agent, and in particular extract of flowering heads of Filipendula ulmaria.

The tonic agent of mucous membranes and pharyngeal tissues is rose hips. The oral composition contains between 0.01 and 5% of tonic agent, and in particular of rose hips.

The oral composition is in the form of an aerosol, more particularly a foam.

A preferred oral composition contains:

about 1 to about 5%, and preferably about 3%, of carrageenans;

from about 1 to about 10%, and preferably about 5%, of phosphatidylcholine;

about 1 to about 5%, and preferably about 3%, of Filipendula ulmaria; from about 0.01 to about 5%, and preferably about 2%, of rose hips.

The composition of the oral spray lubricates the walls of the pharynx (uvula) and increase the tone of smooth muscle structures throughout the night thanks to the bioadhesive action of carrageenans. The nasal spray reduces nasal congestion, reduces chronic inflammation and lubricates the walls to facilitate the passage of airflow during inspiration and expiration. The invention thus also relates to a pack or a kit, or a set, comprising the two preceding compositions and a user manual so as to offer subjects suffering from snoring a treatment based on their combined action allowing s' to attack, simultaneously, the two causes of the noise caused by the big snorers. The two products that make up this kit or pack can be used in a specific order or on the contrary in an unordered manner.

The compositions composing this pack may be packaged in a container comprising several enclosures, or in separate containers. Containers may be packaged in a single package.

This combination of compositions makes it possible for the first time to treat the interactions between the nasal and pharyngeal physiological changes that cause snoring in large snorers. Indeed, there are several "vicious circles" that install progressively, reinforced by bouts of obstruction of the upper respiratory tract that induce changes in airflow. Only the combination of the technical solutions provided by the invention makes it possible to act simultaneously on the causes of snoring in order to significantly reduce, or even eliminate, the noise of snoring in loud snorers.

In the present invention, unless otherwise indicated, the% are% by weight relative to the total weight of the composition.

Other features of the invention will become apparent examples of nasal and oral compositions that follow. Nose composition Big Snore (nose spray) [qsp: enough for ...]

Oral composition, spray throat. [qsp: sufficient quantity for ...]

Claims

1) Composition for combating snoring, characterized in that it comprises: a first substance or combination of substances providing a decongestant action to increase the nasal light by a sympathetic action on the smooth muscles, an action of vasoconstriction of blood vessels and local anti-inflammatory action to decrease the exaggerated secretion of mucus and vasodilator substances;

- a second substance or combination of substances ensuring the reduction of the air resistance at the nasal valve and the middle and lower horns by the formation of a "sliding mat" and the lubrication of the tissues of the nasal passages;

2) Composition according to claim 1, characterized in that the first substance or combination of substances is chosen from the group comprising: bromelain, an extract of Ruscus aculeatus and rutin

3) Composition according to claim 1 or 2, characterized in that the second substance or combination of substances is selected from the group comprising: sea water, glycerin and phosphatidylcholine.

4) Composition according to any one of claims 1 to 3, characterized in that the third Substance or combination of substances is selected from the group of carrageenans.

5) Composition according to any one of claims 1 to 4, characterized in that: - Bromelain, if present, represents of the order of 0.01 to 5% and preferably of the order of 0, 15% by weight of the composition,

the ruscus extract, if it is present, represents of the order of 0.01 to 5% and preferably of the order of 0.50% by weight of the composition, rutin, if it is present , is in the range of 0.01 to 5% and preferably of the order of 0.15% by weight of the composition, at least one of the above substances being present in the composition.

6) Composition according to any one of claims 1 to 5, characterized in that:

seawater, if it is present, represents of the order of 0.1 to 10% and preferably of the order of 1% by weight of the composition,

the glycerin, if it is present, represents from 1 to 10% and preferably from about 2.65% by weight of the composition; phosphatidylcholine, if it is present, represents of the order of 0 , 5 to 10% and preferably of the order of 1.66% by weight of the composition, at least one of the above substances being present in the composition.

7) Composition according to any one of the preceding claims, characterized in that the carrageenans are of the order of 0.1 to 10% and preferably of the order of 1% of the composition. 8) Composition according to any one of the preceding claims, characterized in that it is in the form of a nasal spray.

9) Use of a nasal composition according to any one of claims 1 to 8 for the treatment or prevention of snoring in a subject, more particularly in a large snorer, said nasal composition being received by said subject in association with a oral composition against snoring.

10) Use according to claim 9, characterized in that the oral composition against snoring comprises at least one lubricating substance and at least one bioadhesive substance capable of adhering said lubricant to the mucocilliary cells located at the level of the pharynx.

11) Use according to claim 10, characterized in that the bioadhesive substance is selected from the group consisting of: polysaccharides, cellulose derivatives, acrylic derivatives or protein derivatives.

12) Use according to claim 11, characterized in that the bioadhesive substance is a polysaccharide belonging to the carrageenan family.

13) Use according to any one of claims 10 to 12, characterized in that the oral composition contains from 0.5 to 20% of bioadhesive substance, and in particular of carrageenans. 14) Use according to claim 13, characterized in that the oral composition contains about 1 to 5%, and preferably about 1.5 to 3%, of bioadhesive substance, and in particular carrageenans.

15) Use according to claim 13, characterized in that the oral composition contains about 5 to 20%, and about 10 to 15% of bioadhesive substance, and in particular carrageenans.

16) Use according to any one of claims 10 to 15, characterized in that the lubricating substance is a surfactant having a polar portion and a hydrophobic portion.

17) Use according to claim 16, characterized in that the polar part of the surfactant is selected from the group consisting of: glucose, sucrose, lactose, glycerol, xylose, peptides, amino acids, nucleotides.

18) Use according to claim 16, characterized in that the hydrophobic part is selected from the group comprising: fatty acids, a fatty alcohol, a fatty amine, esters, glycerides, phospholipids.

19) Use according to claim 18, characterized in that the hydrophobic part consists of phospholipids, for example phosphatidylcholine.

20) Use according to any one of claims 10 to 19, characterized in that the composition oral contains about 0.5 to 20% of lubricating substance, and in particular phosphatidylcholine.

21) Use according to claim 20, characterized in that the oral composition preferably contains from 2 to 10% of lubricating substance, and in particular phosphatidylcholine.

22) Use according to any one of claims 10 to 21, characterized in that the oral composition further comprises one or more agent (s) anti-inflammatory (s) and / or tonic (s) mucous membranes and pharyngeal tissue.

23) Use according to claim 22, characterized in that the anti-inflammatory agent is an extract of Filipendula ulmaria.

24) Use according to claim 23, characterized in that said extract is an extract of flowering heads of Filipendula ulmaria.

25) Use according to any one of claims 22 to 24, characterized in that the oral composition contains from 0.5 to 5% of anti-inflammatory agent, and in particular extract of flowering heads of Filipendula ulmaria.

26) Use according to claim 22, characterized in that the mucosal tonic agent and the pharynx tissues is rose hips.

27) Use according to claim 22 or claim 23, characterized in that the oral composition contains between 0.5 and 5% of tonic agent, and in particular of rose hips.

28) Use according to any one of claims 10 to 17, characterized in that the oral composition is in the form of a foam.

29) Pack comprising at least one nasal composition as defined in any one of claims 1 to 9 and at least one oral composition as defined in any one of claims 11 to 28, and a user guide.